Safety and efficacy of erythropoietin in children with chronic renal failure. Pediatr Nephrol 1999 Feb;13(2):143-7
Date
05/06/1999Pubmed ID
10229004DOI
10.1007/s004670050583Scopus ID
2-s2.0-0033042927 (requires institutional sign-in at Scopus site) 51 CitationsAbstract
A prospective randomized study of the use of recombinant human erythropoietin (rHuEPO) in children with chronic renal disease was conducted to assess dosing requirements and side effects. Forty-four children with chronic renal failure, aged 4 months to 21 years, were studied. Twenty-five patients were pre dialysis, 10 on peritoneal dialysis, and 9 on hemodialysis. Patients received either 150 U/kg per week or 450 U/kg per week divided thrice weekly of rHuEPO for 12 weeks or until target hemoglobin (Hb) was attained. Dose was then adjusted to maintain a normal Hb. Eighty-two percent of patients reached target Hb by 7.9+/-5.6 weeks (mean+/-SD); 95% of patients in the high-dose group and 66% in the low-dose group reached target Hb within 12 weeks. The overall median rHuEPO dose at target Hb was 150 U/kg per week. Hemodialysis patients tended to require more rHuEPO to maintain a normal Hb (median 250 U/kg per week). Transfusion requirements and panel-reactive antibody levels decreased during the 12 weeks. Iron deficiency and/or hypertension occurred in 30% of children. In conclusion, rHuEPO at 150 U/kg per week is safe and effective in treating anemia in children with chronic renal disease.
Author List
Brandt JR, Avner ED, Hickman RO, Watkins SLAuthor
Ellis D. Avner MD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Anemia
Blood Transfusion
Child
Child, Preschool
Creatinine
Erythropoietin
Female
Hemoglobins
Humans
Kidney Failure, Chronic
Male
Prospective Studies
Recombinant Proteins
Reticulocyte Count
